Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 50NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Myasthenia Gravis 3Leukemia 3Myelodysplastic Syndromes 2Lymphoma 2Graft vs Host Disease 2Thymic aplasia 1Skin Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Erectile Dysfunction 1Dermatitis, Atopic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Methotrexate 6ruxolitinib 4ibrutinib 4Mycophenolic Acid 3Cyclosporine 3Transplantation Conditioning 2Tacrolimus 2Sirolimus 2Prednisone 2Methylprednisolone 2Cyclophosphamide 2Calcineurin Inhibitors 2thymoglobulin 1siplizumab 1remestemcel-l 1milatuzumab 1itacitinib 1eritoran 1axatilimab 1angiotensin I (1-7) 1Saline Solution 1Rituximab 1Radiotherapy 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1Panobinostat 1KRN 7000 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Graft vs Host Disease × Tacrolimus × Clear all
NCT02663622 2024-01-23

MK-7110-002

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
44 enrolled 27 charts
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

NCT00136903 2022-01-31

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Mesoblast, Ltd.

Phase 2 Completed
32 enrolled
LymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡